{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:47:16Z","timestamp":1790264836046,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,5]]},"DOI":"10.1182\/blood.2019001861","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T23:55:27Z","timestamp":1570060527000},"page":"2107-2111","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["The poor outcome in high molecular risk, hydroxycarbamide-resistant\/intolerant ET is not ameliorated by ruxolitinib"],"prefix":"10.1182","volume":"134","author":[{"given":"Jennifer M.","family":"O\u2019Sullivan","sequence":"first","affiliation":[{"name":"Department of Haematology, Guy\u2019s and St. Thomas\u2019 National Health Service (NHS) Foundation Trust, London, United Kingdom;"},{"name":"Haematopoietic Stem Cell Biology Laboratory and"},{"name":"Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Hamblin","sequence":"additional","affiliation":[{"name":"Oxford Molecular Diagnostics Centre, Oxford, United Kingdom;"},{"name":"National Institute for Health Research (NIHR) Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Yap","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom;"},{"name":"The Institute of Cancer Research, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Fox","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-4193","authenticated-orcid":false,"given":"Rebecca","family":"Boucher","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anesh","family":"Panchal","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah","family":"Alimam","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy\u2019s and St. Thomas\u2019 National Health Service (NHS) Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Dreau","sequence":"additional","affiliation":[{"name":"Oxford Molecular Diagnostics Centre, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Howard","sequence":"additional","affiliation":[{"name":"Oxford Molecular Diagnostics Centre, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Ware","sequence":"additional","affiliation":[{"name":"Oxford Molecular Diagnostics Centre, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-0204","authenticated-orcid":false,"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[{"name":"Department of Haematology, Queen\u2019s University, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy\u2019s and St. Thomas\u2019 National Health Service (NHS) Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-1002","authenticated-orcid":false,"given":"Adam J.","family":"Mead","sequence":"additional","affiliation":[{"name":"Haematopoietic Stem Cell Biology Laboratory and"},{"name":"Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom;"},{"name":"National Institute for Health Research (NIHR) Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2019120506585071000_B1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"issue":"22","key":"2019120506585071000_B2","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019120506585071000_B3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2141.2011.08858.x","article-title":"Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients","volume":"156","author":"Palandri","year":"2012","journal-title":"Br J Haematol"},{"issue":"10","key":"2019120506585071000_B4","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019120506585071000_B5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3324\/haematol.2014.118299","article-title":"Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations","volume":"100","author":"Al Assaf","year":"2015","journal-title":"Haematologica"},{"issue":"20","key":"2019120506585071000_B6","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"suppl 15","key":"2019120506585071000_B7","doi-asserted-by":"crossref","first-page":"e18565","DOI":"10.1200\/JCO.2017.35.15_suppl.e18565","article-title":"Treatment of essential thrombocytopenia patients intolerant\/resistant to hydroxyurea: a physician survey [abstract]","volume":"35","author":"Nejadnik","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019120506585071000_B8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","article-title":"Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia","volume":"152","author":"Hern\u00e1ndez-Boluda","year":"2011","journal-title":"Br J Haematol"},{"issue":"17","key":"2019120506585071000_B9","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"2019120506585071000_B10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2019120506585071000_B11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"2019120506585071000_B12","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2019120506585071000_B13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019120506585071000_B14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"issue":"15","key":"2019120506585071000_B15","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"2019120506585071000_B16","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V128.22.1952.1952","article-title":"Role of non-driver mutations and JAK2V617F allele burden in myelofibrotic and acute myeloid transformation of patients with polycythemia vera and essential thrombocythemia [abstract]","volume":"128","author":"Sen\u00edn","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019120506585071000_B17","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.3324\/haematol.2015.138958","article-title":"Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome","volume":"101","author":"Asp","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2019120506585071000_B18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2017.230","article-title":"Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status","volume":"32","author":"Kubesova","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2019120506585071000_B19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","article-title":"Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up","volume":"97","author":"Sen\u00edn","year":"2018","journal-title":"Ann Hematol"},{"issue":"24","key":"2019120506585071000_B20","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019120506585071000_B21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2019120506585071000_B22","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/leu.2013.120","article-title":"Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis","volume":"27","author":"Bros\u00e9us","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2019120506585071000_B23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/23\/2107\/1545315\/bloodbld2019001861.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/23\/2107\/1545315\/bloodbld2019001861.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T06:59:10Z","timestamp":1575529150000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/23\/2107\/375014\/The-poor-outcome-in-high-molecular-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":23,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019001861","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]}}}